LOTRISONE Drug Patent Profile

When do Lotrisone patents expire, and what generic alternatives are available?

Lotrisone is a drug marketed by Organon and Merck Sharp Dohme and is included in two NDAs.

The generic ingredient in LOTRISONE is betamethasone dipropionate; clotrimazole. There are sixty-six drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; clotrimazole profile page.

Summary for LOTRISONE

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	72
Clinical Trials:	1
Drug Prices:	Drug price information for LOTRISONE
Drug Sales Revenues:	Drug sales revenues for LOTRISONE
What excipients (inactive ingredients) are in LOTRISONE?	LOTRISONE excipients list
DailyMed Link:	LOTRISONE at DailyMed

See drug prices for LOTRISONE

See drug sales revenues for LOTRISONE

Recent Clinical Trials for LOTRISONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jilin University	Phase 2

See all LOTRISONE clinical trials

US Patents and Regulatory Information for LOTRISONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	LOTRISONE	betamethasone dipropionate; clotrimazole	CREAM;TOPICAL	018827-001	Jul 10, 1984		DISCN	Yes	No
Merck Sharp Dohme	LOTRISONE	betamethasone dipropionate; clotrimazole	LOTION;TOPICAL	020010-001	Dec 8, 2000		DISCN	Yes	No

Expired US Patents for LOTRISONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	LOTRISONE	betamethasone dipropionate; clotrimazole	CREAM;TOPICAL	018827-001	Jul 10, 1984	3,660,577
Organon	LOTRISONE	betamethasone dipropionate; clotrimazole	CREAM;TOPICAL	018827-001	Jul 10, 1984	3,705,172
Organon	LOTRISONE	betamethasone dipropionate; clotrimazole	CREAM;TOPICAL	018827-001	Jul 10, 1984	4,298,604

International Patents for LOTRISONE

See the table below for patents covering LOTRISONE around the world.

Country	Patent Number	Title	Estimated Expiration
Sweden	341632
Australia	7605081
Spain	358154

Market Dynamics and Financial Trajectory for LOTRISONE

Last updated: January 31, 2026

Executive Summary

LOTRISONE (clotrimazole and betamethasone dipropionate), a topical antifungal and corticosteroid combination, has maintained a significant presence in the antifungal dermatological market since its FDA approval in 1992. This report assesses its current market landscape, competitive positioning, financial performance, and future growth potential, considering evolving market dynamics such as product lifecycle, patent status, generic entry, regulatory policies, and emerging treatment alternatives.

1. Product Overview and Market Position

Attribute	Details
Active Ingredients	Clotrimazole (antifungal), Betamethasone dipropionate (corticosteroid)
Indications	Tinea corporis, tinea cruris, tinea pedis, dermatitis, other superficial fungal infections
Formulation	Topical cream (30g, 45g, 60g tubes)
Market Launch	1992 (FDA approval in the United States)

Market Position:

• Competes primarily in the topical antifungal segment for dermatological conditions with anti-inflammatory properties.
• Historically held a strong market share owing to its combination therapy benefits.
• Patent protection expired in the early 2000s, leading to increased generic competition.

2. Market Dynamics

A. Market Size and Growth Trends

Year	Global Topical Antifungal Market (USD billions)	CAGR (2018–2023)	Segment Share (Topical Antifungals)	Notes
2018	2.1	4.5%	100%	Includes monotherapy and combination products
2023	2.6	—	—	Market estimated to reach USD 3.3 billion by 2026 [1]

Key Observations:

• Moderate growth driven by increasing prevalence of fungal skin infections.
• Aging populations and rising dermatological conditions contribute to demand.
• Market expansion into emerging markets supports growth projections.

B. Competitive Landscape

Company	Key Products	Market Share (Est.)	Notable Attributes
Bayer (original developer)	Lotrisone (generic and branded)	~40%	Extensive distribution network
Mylan, Teva, Sandoz	Generic versions	40–50% (combined)	Price competition, regulatory approvals
Others	Niche and regional brands	Remaining	Regional preferences, OTC brands

Market Shifts:

• Patent expiration led to multiple generics.
• Price erosion impacts revenue margins.
• Shift towards broader antifungal classes and novel formulations.

C. Patent and Regulatory Milestones

Year	Event	Impact
1992	FDA approval for Lotrisone	Market entry, monopoly for initial patent period
2000s	Patent expiry; launch of generics	Market commoditization, increased competition
2015–2023	Regulatory updates, off-label use scrutiny	Modest impact on approved indications, enhanced oversight

D. Pricing and Revenue Estimates

Year	Estimated Global Revenue (USD millions)	Key Factors
2018	150	Patented exclusivity ending, moderate market penetration
2023	70–100	Price erosion from generics, competitive pressures
2026 (projected)	Approx. USD 50–80	Continued generic dominance, plateauing demand

3. Drivers and Restraints

Drivers

• Increasing Incidence of Fungal Skin Infections: Growing prevalence driven by humid climates, lifestyle factors, and aging populations bolster the market.
• Convenience of Combination Therapy: Patients prefer combined formulations reducing treatment complexity and improving adherence.
• Expanding Generic Market: Price competitiveness drives volume sales but limits revenue growth for branded formulations.

Restraints

• Patent Loss and Generics: Loss of patent protection substantially reduces pricing power.
• Emerging Alternatives: New antifungal agents, like terbinafine and newer azoles, challenge Lotrisone’s dominance.
• Regulatory Environment: Strict regulations on corticosteroid use in topical formulations may impact future approvals.

4. Future Outlook and Growth Potential

A. Innovation and Formulation Developments

Innovation Area	Potential Impact
Non-steroidal antifungal formulations	Reduce corticosteroid-associated risks, meet regulatory scrutiny
Once-daily topical formulations	Improve patient adherence, expand market share
Biosimilars and generic adaptations	Lower costs, increase accessibility

B. Market Expansion Opportunities

• Emerging Markets: Rapid healthcare infrastructure development in Asia-Pacific, Latin America, offers growth avenues.
• Chronic Use Indications: Growing cases of dermatitis and other chronic skin conditions imply demand stability.
• OTC Transition: Shifting certain formulations to over-the-counter status can broaden consumer access.

C. Risks and Challenges

• Pricing Pressures: Intense competition may lead to further margins compression.
• Regulatory Restrictions: Global regulatory agencies may impose tighter controls on corticosteroid use.
• Efficacy and Safety Concerns: Long-term corticosteroid side effects could influence prescribing trends.

5. Comparative Analysis with Alternative Therapies

Therapy Type	Examples	Advantages	Limitations
Azole antifungals	Ketoconazole, itraconazole	Broad spectrum, oral formulations available	Potential resistance, drug interactions
Allylamines (e.g., terbinafine)	Topical and oral formulations	Higher efficacy for certain candidiasis	Cost, potential hepatotoxicity
Corticosteroid combinations	Lotrisone, Clotrimazole with betamethasone	Anti-inflammatory, rapid symptom relief	Steroid side effects with prolonged use

6. Financial Performance and Proprietary Considerations

Aspect	Details
Revenue Contribution (Estimate)	~USD 70–100 million in 2023 (globally)
Patent Status	Expired; generic competition dominant
R&D Investment	Limited; primarily relies on generic manufacturing
Licensing and Partnerships	Minimal, with strategic focus on core competencies

7. Strategic Recommendations

• Focus on Formulation Innovation: Develop steroid-sparing formulations or alternative delivery systems.
• Expand in Emerging Markets: Tailor marketing strategies and affordability programs to penetrate high-growth regions.
• Monitor Regulatory Trends: Anticipate regulations that could restrict corticosteroid use, innovating accordingly.
• Leverage Brand Trust: Highlight efficacy and safety records to maintain premium positioning where feasible.

Key Takeaways

• The global topical antifungal market is growing modestly, driven by rising skin infections and aging demographics.
• Patent expiration of LOTRISONE has catalyzed significant generic entry, compressing revenue margins.
• Competition from newer antifungal agents and formulations presents both challenges and opportunities.
• Despite revenue decline, ongoing demand sustains profitability, especially in markets with limited generic penetration.
• Innovation, strategic market expansion, and regulatory adaptation are critical for future growth.

---

FAQs

Q1: What is the current market share of LOTRISONE among topical antifungal treatments?
A: Exact figures are proprietary; however, estimations suggest that branded LOTRISONE has a <10% share compared to the combined dominance of multiple generic formulations, approximating a 40–50% market share for all Lotrisone variants combined, with the rest occupied by generics [1].

Q2: How does patent expiry affect LOTRISONE's profitability?
A: Patent expiry in the early 2000s introduced numerous generics, leading to significant price erosion and pressure on revenue streams. The branded product's market share diminished, though it retains some premium positioning in certain markets due to brand recognition.

Q3: What are emerging trends impacting the future of LOTRISONE?
A: Trends include formulation innovations reducing corticosteroid content, shifting to OTC classifications, and the advent of alternative antifungal agents with broader spectrum or fewer side effects.

Q4: Which regions present the highest growth potential for topical antifungals?
A: Asia-Pacific and Latin America exhibit rapid growth due to increasing infection prevalence, healthcare access improvements, and expanding dermatology markets.

Q5: What regulatory considerations could influence LOTRISONE’s market?
A: Increased scrutiny over corticosteroid use, restrictions on combination therapies, and potential class-specific regulations could impact product formulary status and marketing strategies worldwide.

---

References

[1] MarketsandMarkets. "Antifungal Drugs Market by Type, Application, and Region - Global Forecast to 2026," 2022.